Impact of government-organized screening programs on the economic burden of cervical cancer across five disease courses: a multistage regression and mediation analysis.

IF 8.4 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Mingjie Dong, Jiaxin Xie, Xuelian Zhao, Fanghui Zhao
{"title":"Impact of government-organized screening programs on the economic burden of cervical cancer across five disease courses: a multistage regression and mediation analysis.","authors":"Mingjie Dong, Jiaxin Xie, Xuelian Zhao, Fanghui Zhao","doi":"10.20892/j.issn.2095-3941.2025.0418","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of government-organized screening on the economic burden among patients with cervical cancer and precancerous lesions, and explore mediating pathways across diagnosis, initial treatment, radiotherapy/chemotherapy, follow-up, and recurrence/progression/metastasis.</p><p><strong>Methods: </strong>A multicentre, nationwide survey across 5 disease courses was conducted from 26 hospitals in China. Multivariable regression and structural equation modeling were used to assess the effects of government-organized screening on economic burden by comparing government-organized screening with workplace check-up, self-paid check-up, and symptom-based detection.</p><p><strong>Results: </strong>Workplace check-up, self-paid check-up, and symptom-based detection were associated with progressively higher costs across diagnosis [<i>β</i>: 1.10, 95% confidence interval (CI): 0.54-1.67; <i>β</i>: 1.46, 95% CI: 1.00-1.92; and <i>β</i>: 1.68, 95% CI: 1.25-2.11, respectively], initial treatment (<i>β</i>: 0.36, 95% CI: 0.18-0.55; <i>β</i>: 0.51, 95% CI: 0.35-0.66; and <i>β</i>: 0.56, 95% CI: 0.42-0.70, respectively), and follow-up (<i>β</i>: 0.63, 95% CI: 0.38-0.88; <i>β</i>: 0.83, 95% CI: 0.61-1.04; and <i>β</i>: 0.85, 95% CI: 0.65-1.06, respectively) compared to government-organized screening (all <i>P</i> < 0.05). Earlier clinical staging and greater use of lower-level hospitals mediated 44.74%-54.97% of cost differences in diagnosis, 73.27%-85.04% in initial treatment, and 30.38%-54.73% in follow-up. Fifteen percent of the cost differences during initial treatment were related to lower overtreatment for precancerous lesions.</p><p><strong>Conclusions: </strong>Government-led cervical cancer screening was associated with lower economic burden with pathways involving earlier-stage diagnosis, reduced overtreatment, and decreased reliance on higher-level hospitals, suggesting potential clinical benefits, efficient resource use, and improved equity in cancer care.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501897/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biology & Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20892/j.issn.2095-3941.2025.0418","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the impact of government-organized screening on the economic burden among patients with cervical cancer and precancerous lesions, and explore mediating pathways across diagnosis, initial treatment, radiotherapy/chemotherapy, follow-up, and recurrence/progression/metastasis.

Methods: A multicentre, nationwide survey across 5 disease courses was conducted from 26 hospitals in China. Multivariable regression and structural equation modeling were used to assess the effects of government-organized screening on economic burden by comparing government-organized screening with workplace check-up, self-paid check-up, and symptom-based detection.

Results: Workplace check-up, self-paid check-up, and symptom-based detection were associated with progressively higher costs across diagnosis [β: 1.10, 95% confidence interval (CI): 0.54-1.67; β: 1.46, 95% CI: 1.00-1.92; and β: 1.68, 95% CI: 1.25-2.11, respectively], initial treatment (β: 0.36, 95% CI: 0.18-0.55; β: 0.51, 95% CI: 0.35-0.66; and β: 0.56, 95% CI: 0.42-0.70, respectively), and follow-up (β: 0.63, 95% CI: 0.38-0.88; β: 0.83, 95% CI: 0.61-1.04; and β: 0.85, 95% CI: 0.65-1.06, respectively) compared to government-organized screening (all P < 0.05). Earlier clinical staging and greater use of lower-level hospitals mediated 44.74%-54.97% of cost differences in diagnosis, 73.27%-85.04% in initial treatment, and 30.38%-54.73% in follow-up. Fifteen percent of the cost differences during initial treatment were related to lower overtreatment for precancerous lesions.

Conclusions: Government-led cervical cancer screening was associated with lower economic burden with pathways involving earlier-stage diagnosis, reduced overtreatment, and decreased reliance on higher-level hospitals, suggesting potential clinical benefits, efficient resource use, and improved equity in cancer care.

政府组织的筛查项目对五种疾病病程宫颈癌经济负担的影响:多阶段回归和中介分析
目的:评价政府组织筛查对宫颈癌及癌前病变患者经济负担的影响,探讨诊断、初始治疗、放化疗、随访、复发/进展/转移等过程中的中介途径。方法:在全国26家医院进行5个病程的多中心调查。采用多变量回归和结构方程模型,通过比较政府组织筛查与工作场所体检、自费体检和基于症状的检测,评估政府组织筛查对经济负担的影响。结果:工作场所检查、自费检查和基于症状的检测与整个诊断过程中逐渐增加的成本相关[β: 1.10, 95%可信区间(CI): 0.54-1.67;β: 1.46, 95% ci: 1.00-1.92;与政府组织的筛查相比,初始治疗(β: 0.36, 95% CI: 0.18-0.55; β: 0.51, 95% CI: 0.35-0.66; β: 0.56, 95% CI: 0.42-0.70)和随访(β: 0.63, 95% CI: 0.38-0.88; β: 0.83, 95% CI: 0.61-1.04; β: 0.85, 95% CI: 0.65-1.06)(均P < 0.05)。较早的临床分期和较多的基层医院使用介导了44.74% ~ 54.97%的诊断成本差异,73.27% ~ 85.04%的初始治疗成本差异,30.38% ~ 54.73%的随访成本差异。初始治疗期间15%的费用差异与较低的癌前病变过度治疗有关。结论:政府主导的宫颈癌筛查与较低的经济负担相关,包括早期诊断,减少过度治疗,减少对高水平医院的依赖,这表明潜在的临床效益,有效的资源利用,提高了癌症护理的公平性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Biology & Medicine
Cancer Biology & Medicine Medicine-Oncology
CiteScore
9.80
自引率
3.60%
发文量
1143
审稿时长
12 weeks
期刊介绍: Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信